Premium
Severe oral lichen planus: remission and maintenance with Vitamin A analogues
Author(s) -
Sloberg K.,
Hersle K.,
Mobacken H.,
Thilander H.
Publication year - 1983
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/j.1600-0714.1983.tb00359.x
Subject(s) - etretinate , medicine , oral lichen planus , adverse effect , oral administration , gastroenterology , dermatology , complete remission , surgery , chemotherapy , psoriasis
Twenty‐five patients with chronic oral lichen planus, usually of the atrophic‐erosive type, were treated for 2 months with Etretinate® 0.6 mg/kg b.w./day, followed for 4 months by Etretinate® 0.3 mg/kg/day, or 0.1% Tretinoin® in an adhesive base. Complete resolution or improvement was seen in 85% of the lesions after first treatment. The number of patients with oral soreness and pain was significantly reduced (p < 0.001). During the second treatment, the improvement was maintained or even increased in about 70% of the patients, irrespective of the mode of treatment. Treatment was discontinued in one patient owing to moderately increased serum transaminase levels. The number of drug‐related drop‐outs was significantly lower than in a previous study utilizing an etretinate dose of about 1 mg/kg/day (p < 0.05). Other adverse effects were minor and tolerable. Retinoids offer an effective mode of therapy for severe oral lichen planus.